10 chapters across the catalog
A 2019 clip of Kamala Harris discussing the seizure of drug patents is linked to the Biden administration's 2023 "March-in rights" policy. This policy allows the government to seize patents for medicines developed with federal funding if prices are deemed too high. It is noted that the intelligence community has historically suppressed patents for national security reasons without public challenge.
A pharmaceutical industry insider provides a breakdown of the differences between Ozempic and Wegovy, noting they are the same molecule (Semaglutide) but dosed differently for diabetes versus obesity. The source explains insurance hurdles, the "Ozempic face" phenomenon, and warns that compounding pharmacies are not sourcing their Semaglutide from the patent holder, Novo Nordisk.
The pharmaceutical product Marinol, a synthetic form of THC known as dronabinol, is identified as a competitor to natural marijuana. Solvay Pharmaceuticals, the maker of Marinol, was recently acquired by Abbott Labs. The segment suggests that the government's continued crackdown on natural marijuana is intended to protect the market share of patented synthetic alternatives.
Marijuana Cultivation, Addiction and Pharma Patents
The discussion shifts to the economics of marijuana, noting that most product in California is grown locally in counties like Mendocino rather than smuggled from Mexico. Theories are explored regarding the pharmaceutical industry's opposition to legalization due to existing government patents on synthetic cannabinoids.
The Orphan Drug Act is being exploited by companies like KV Pharmaceuticals to repatent old, cheap compounds and raise prices from $30 to $30,000. The FDA is criticized for allowing patent exclusivity on existing drugs and failing to protect the public from corporate monopolies.
Alzheimer's Drug Repurposing, Leukine Patent, Pharmaceutical Industry
The drug Leukine, originally for rheumatoid arthritis, is being promoted as a potential treatment for Alzheimer's disease. This "discovery" coincides with the drug's patent expiration in 2012. The hosts argue this is a common pharmaceutical industry tactic to repatent old drugs for new uses to prevent generic competition and maintain high prices.
Pharmaceutical Patent Extensions and Mitch McConnell
The House of Representatives passed an amendment to a tax bill designed to help a single pharmaceutical company maintain control over a blood-thinning drug patent. While CBS News framed this as a failure of the Republican party, the hosts argue the real story is the systemic corruption of Congress extending patents to prevent cheaper generic drugs from entering the market. Senator Mitch McConnell is criticized for dismissing public disapproval of Congressional ethics.
Eli Lilly faces a significant "patent cliff" as several brand-name drugs lose market exclusivity through 2020. The discussion explores allegations that major pharmaceutical companies bribe generic manufacturers to delay the release of cheaper alternatives, allowing the original patent holders to maintain high prices.
Missouri Nuclear Reactor Fire and Vaccine Patents
An electrical fire at a nuclear reactor in Missouri, occurring amidst regional flooding, has raised concerns about potential safety risks. Meanwhile, the pharmaceutical industry is reportedly lobbying Congress to extend patents on various drugs and vaccines. The hosts suggest that the push for universal vaccination programs is driven more by corporate profit motives than public health needs.
Pharmaceutical Industry Business Models and Preventative Medicine
The pharmaceutical industry is analyzed as transitioning toward a preventative medicine model to maximize revenue as traditional drug patents expire. By focusing on vaccines for conditions like nicotine addiction or HPV, companies can market products to healthy populations. Investors are encouraged to review CEO PowerPoint presentations and annual reports to understand this strategic shift toward long-term preventative drug use.
